By Connor Hart
Shares of Trinity Biotech climbed after the company released what it called compelling results from a study of its next-generation continuous glucose monitoring system, a device used for diabetes management that measures blood sugar levels in real time.
The stock was up 41%, to $1.07, in midday trading Tuesday. Shares are down 52% in the past 52 weeks.
The Dublin-based biotechnology company on Tuesday said the new system demonstrated better signal quality, accuracy and consistency than did previous generations in a recent trial involving 30 diabetic participants.
The new system also features a reusable applicator and a rechargeable wearable transmitter, eliminating costly disposable components and allowing the product to be made at a significantly lower cost, Trinity said.
Moving forward, the company said it expects to complete further clinical trials on the device. It remains on track to file for regulatory approval in the EU in 2025, and in the U.S. in 2026.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 28, 2025 11:59 ET (16:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。